rs2297902

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1

The NM_000069.3(CACNA1S):​c.2748C>T​(p.His916His) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0199 in 1,608,184 control chromosomes in the GnomAD database, including 1,214 homozygotes. In-silico tool predicts a benign outcome for this variant. 1/1 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.023 ( 172 hom., cov: 32)
Exomes 𝑓: 0.020 ( 1042 hom. )

Consequence

CACNA1S
NM_000069.3 splice_region, synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:14

Conservation

PhyloP100: 0.533

Publications

19 publications found
Variant links:
Genes affected
CACNA1S (HGNC:1397): (calcium voltage-gated channel subunit alpha1 S) This gene encodes one of the five subunits of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Mutations in this gene have been associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis and malignant hyperthermia susceptibility. [provided by RefSeq, Jul 2008]
CACNA1S Gene-Disease associations (from GenCC):
  • congenital myopathy 18
    Inheritance: AD, AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • hypokalemic periodic paralysis, type 1
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
  • malignant hyperthermia, susceptibility to, 5
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • congenital myopathy
    Inheritance: SD, AR, AD Classification: STRONG Submitted by: Illumina, Genomics England PanelApp
  • hypokalemic periodic paralysis
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.33).
BP6
Variant 1-201065943-G-A is Benign according to our data. Variant chr1-201065943-G-A is described in ClinVar as Benign. ClinVar VariationId is 254822.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=0.533 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.192 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CACNA1SNM_000069.3 linkc.2748C>T p.His916His splice_region_variant, synonymous_variant Exon 22 of 44 ENST00000362061.4 NP_000060.2 Q13698
CACNA1SXM_005245478.4 linkc.2748C>T p.His916His splice_region_variant, synonymous_variant Exon 22 of 43 XP_005245535.1 B1ALM3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CACNA1SENST00000362061.4 linkc.2748C>T p.His916His splice_region_variant, synonymous_variant Exon 22 of 44 1 NM_000069.3 ENSP00000355192.3 Q13698

Frequencies

GnomAD3 genomes
AF:
0.0230
AC:
3496
AN:
152172
Hom.:
162
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0109
Gnomad AMI
AF:
0.00110
Gnomad AMR
AF:
0.0352
Gnomad ASJ
AF:
0.0193
Gnomad EAS
AF:
0.202
Gnomad SAS
AF:
0.0319
Gnomad FIN
AF:
0.0367
Gnomad MID
AF:
0.0538
Gnomad NFE
AF:
0.0113
Gnomad OTH
AF:
0.0320
GnomAD2 exomes
AF:
0.0383
AC:
9443
AN:
246738
AF XY:
0.0362
show subpopulations
Gnomad AFR exome
AF:
0.0114
Gnomad AMR exome
AF:
0.0644
Gnomad ASJ exome
AF:
0.0195
Gnomad EAS exome
AF:
0.199
Gnomad FIN exome
AF:
0.0349
Gnomad NFE exome
AF:
0.0117
Gnomad OTH exome
AF:
0.0308
GnomAD4 exome
AF:
0.0196
AC:
28527
AN:
1455894
Hom.:
1042
Cov.:
30
AF XY:
0.0199
AC XY:
14400
AN XY:
724474
show subpopulations
African (AFR)
AF:
0.0109
AC:
364
AN:
33378
American (AMR)
AF:
0.0620
AC:
2750
AN:
44384
Ashkenazi Jewish (ASJ)
AF:
0.0207
AC:
539
AN:
26066
East Asian (EAS)
AF:
0.194
AC:
7667
AN:
39586
South Asian (SAS)
AF:
0.0349
AC:
2994
AN:
85818
European-Finnish (FIN)
AF:
0.0360
AC:
1917
AN:
53274
Middle Eastern (MID)
AF:
0.0398
AC:
229
AN:
5752
European-Non Finnish (NFE)
AF:
0.00951
AC:
10528
AN:
1107464
Other (OTH)
AF:
0.0256
AC:
1539
AN:
60172
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.493
Heterozygous variant carriers
0
1482
2964
4446
5928
7410
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
546
1092
1638
2184
2730
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0232
AC:
3526
AN:
152290
Hom.:
172
Cov.:
32
AF XY:
0.0254
AC XY:
1889
AN XY:
74446
show subpopulations
African (AFR)
AF:
0.0110
AC:
459
AN:
41562
American (AMR)
AF:
0.0351
AC:
538
AN:
15308
Ashkenazi Jewish (ASJ)
AF:
0.0193
AC:
67
AN:
3466
East Asian (EAS)
AF:
0.202
AC:
1043
AN:
5164
South Asian (SAS)
AF:
0.0321
AC:
155
AN:
4830
European-Finnish (FIN)
AF:
0.0367
AC:
390
AN:
10614
Middle Eastern (MID)
AF:
0.0578
AC:
17
AN:
294
European-Non Finnish (NFE)
AF:
0.0113
AC:
767
AN:
68026
Other (OTH)
AF:
0.0421
AC:
89
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
164
328
491
655
819
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
44
88
132
176
220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0183
Hom.:
155
Bravo
AF:
0.0255
Asia WGS
AF:
0.116
AC:
403
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:14
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Mar 18, 2016
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

not provided Benign:3
Apr 27, 2018
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Malignant hyperthermia, susceptibility to, 5 Benign:3
Mar 05, 2018
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 05, 2024
All of Us Research Program, National Institutes of Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Hypokalemic periodic paralysis, type 1 Benign:2
Mar 06, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Congenital myopathy 18 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Thyrotoxic periodic paralysis, susceptibility to, 1 Benign:1
Apr 11, 2023
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Malignant hyperthermia, susceptibility to, 5;C3714580:Hypokalemic periodic paralysis, type 1 Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.33
CADD
Benign
10
DANN
Benign
0.89
PhyloP100
0.53
Mutation Taster
=93/7
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs2297902; hg19: chr1-201035071; COSMIC: COSV62937047; API